{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T09:31:30Z","timestamp":1768469490897,"version":"3.49.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T00:00:00Z","timestamp":1614124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T00:00:00Z","timestamp":1614124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s10620-021-06875-w","type":"journal-article","created":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T09:05:09Z","timestamp":1614157509000},"page":"3672-3673","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["More Than Just Heartburn: Does Famotidine Effectively Treat Patients with COVID-19?"],"prefix":"10.1007","volume":"66","author":[{"given":"Robert W.","family":"Malone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,24]]},"reference":[{"key":"6875_CR1","doi-asserted-by":"crossref","unstructured":"Malone RW, Tisdall P, Fremont-Smith P, et al. COVID-19: famotidine, histamine, mast cells, and mechanisms. Frontiers in Pharmacology. 2021 (in Press).","DOI":"10.21203\/rs.3.rs-30934\/v2"},{"key":"6875_CR2","doi-asserted-by":"publisher","unstructured":"Sun S, Chen Y, Hu L, Wu Y, Liang, M, Ahmed MA, Bhan D, Guo A, Yang H, Zuo Y, Yan Y, Zhou Q. Does Famotidine reduce the risk of progression to severe disease, death, and intubation for COVID-19 patients? A systemic review and meta-analysis. Digestive Diseases and Sciences. (Epub ahead of print). doi: https:\/\/doi.org\/10.1007\/s10620-021-6872-2.","DOI":"10.1007\/s10620-021-6872-2"},{"key":"6875_CR3","doi-asserted-by":"crossref","unstructured":"Shoaibi A, Fortin S, Weinstein R, Berlin JA, Ryan P. Comparative effectiveness of famotidine in hospitalized COVID-19 patients. American Journal of Gastroenterology. 2022 (in Press).","DOI":"10.14309\/ajg.0000000000001153"},{"key":"6875_CR4","doi-asserted-by":"crossref","unstructured":"Lee SW, Ha EK, Yeniova A, Oet al. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching Gut. 2021;70:76\u201384.","DOI":"10.1136\/gutjnl-2020-322248"},{"key":"6875_CR5","doi-asserted-by":"crossref","unstructured":"Almario CV, Chey WD, Spiegel BMR. Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors Am J Gastroenterol. 2020;115:1707\u20131715.","DOI":"10.14309\/ajg.0000000000000798"},{"key":"6875_CR6","doi-asserted-by":"crossref","unstructured":"Freedberg DE, Conigliaro J, Wang TC et al. Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: a propensity score matched retrospective cohort study. Gastroenterology. 2020.","DOI":"10.1053\/j.gastro.2020.05.053"},{"key":"6875_CR7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1177\/0885066620973585","volume":"36","author":"P Kory","year":"2021","unstructured":"Kory P, Meduri GU, Iglesias J, Varon J, Marik PE. Clinical and scientific rationale for the \u201cMATH+\u201d hospital treatment protocol for COVID-19. J Intensive Care Med. 2021;36:135\u2013156","journal-title":"J Intensive Care Med."},{"key":"6875_CR8","doi-asserted-by":"crossref","unstructured":"Hogan RB, Hogan RB, Cannon T, et al. Dual-histamine receptor blockade with cetirizine\u2014famotidine reduces pulmonary symptoms in COVID-19 patients. Pulmonary Pharmacology & Therapeutics. 2020:101942.","DOI":"10.1016\/j.pupt.2020.101942"},{"key":"6875_CR9","unstructured":"Tomera KM, Malone R, Kittah JK. Hospitalized COVID-19 patients treated with celecoxib and high dose famotidine adjuvant therapy show significant clinical responses Frontiers in Pharmacology. 2021 (in Press)."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-021-06875-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-021-06875-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-021-06875-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T02:43:59Z","timestamp":1634093039000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-021-06875-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,24]]},"references-count":9,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["6875"],"URL":"https:\/\/doi.org\/10.1007\/s10620-021-06875-w","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,24]]},"assertion":[{"value":"20 January 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}